US Border Rule to End Affordable Canadian Prescriptions

Starting October 22, 2026, a new U.S. Customs and Border Protection rule will prohibit small packages valued at US$800 or less from entering the country duty-free. This change significantly impacts Americans who have long accessed more affordable prescription medications from Canadian pharmacies via mail. The move stems from a trade court ruling that permits the termination of a tariff exemption for such shipments, a measure initially intended to combat smuggling.

Advocates, including Gabriel Levitt of Prescription Justice, express grave concern that this new system, which involves technical platforms and an "importer of record," will complicate or altogether prevent the shipment of essential medications. While the U.S. government states the rule targets illicit drugs like fentanyl, organizations like Prescription Justice urge the FDA and CBP to exercise enforcement discretion for personal prescription drug imports. They emphasize that many Americans, particularly seniors and the uninsured, depend on these more affordable options, and that eliminating this channel could lead to serious health consequences, including people being unable to afford their prescriptions.

Licensed Canadian pharmacies, represented by the Canadian International Pharmacy Association (CIPA), have served American patients for decades, providing essential maintenance medications. The potential loss of this access could force many patients to seek alternative, potentially more expensive, sources for their drugs. This situation highlights a critical disparity in prescription drug pricing between the U.S. and other high-income countries.